Opendata, web and dolomites

TK-NEO SIGNED

Personalized Cancer Immunotherapy through DNA-EP vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TK-NEO project word cloud

Explore the words cloud of the TK-NEO project. It provides you a very rough idea of what is the project "TK-NEO" about.

release    vaccine    validate    ep    lung    vc    sme    locally    license    zero    neo    tumors    week    exclusive    medicine    human    right    efficacy    manufacturing    completion    instrument    proven    stage    tumours    underwent    co    solid    ncvs    tumour    company    solution    confirm    takis    authorization    client    gmp    feasibility    mou    customized    pharma    validation    patients    applicability    sequence    surgery    5m    heterogeneous    anti    neoantigen    cancer    market    sequencing    melanoma    mice    synthesis    strategy    reduce    metastatic    safety    tumor    electroporation    fold    treatment    clinical    protecting    days    rna    precision    chemotherapeutic    total    pricing    constituted    patented    humanized    relapse    dna    ip    maintenance    perfect    boosting    tk    final    first    additional    vaccination    respect    investment    trials    licensing    combining    alternative    carry    tests    therapeutic    financing    form    disease    immune    patient    ncv    immunity   

Project "TK-NEO" data sheet

The following table provides information about the project.

Coordinator
TAKIS SRL 

Organization address
address: VIA DI CASTEL ROMANO 100
city: ROMA
postcode: 128
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TAKIS SRL IT (ROMA) coordinator 50˙000.00

Map

 Project objective

TK-NEO is a DNA-based Neoantigen Cancer Vaccine (NCV), for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours. NCVs are a new form of precision medicine and are a perfect clinical approach for highly heterogeneous tumors in patients with metastatic disease. Takis has developed and patented a unique method for production of patient-specific NCVs based on a 6-week process, from sequencing the specific tumour DNA, synthesis of the right DNA sequence for the specific tumour, delivery through a specific Electroporation (EP) technology used under exclusive license. The solution was proven at pre-clinical stage to reduce to zero a human lung cancer in humanized mice in 60 days and to increase the efficacy several fold with respect to alternative RNA and DNA based NCVs in protecting relapse and boosting immune responses as required for the maintenance of long-term anti-tumor immunity. The strategy to reach the market for TK-NEO is to license the IP of TK-NEO to a large pharma company, after completion of clinical validation trials to demonstrate the applicability and safety of the approach: phase I clinical trials in melanoma are targeted during SME Instrument project, while implementation of a GMP manufacturing to carry out phase II clinical trials and the implementation of the trials will require additional 5M investment. The Total Available Market is constituted by melanoma patients who underwent surgery and first chemotherapeutic treatment, who are estimated in the order of 30.000 patients per year combining EU and US. The objectives of the feasibility study are: 1) to validate the feasibility and the authorization process for the release tests, 2) to confirm investment, cost and pricing for TK-NEO, 3) to define a MoU with VC or with the final client (pharma) for the co-financing of the clinical development of customized TK-NEO and for future licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TK-NEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TK-NEO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More